Bristol-Myers Gets CHMP Positive Opinion for Opdivo Flat Dosing in Melanoma
24 September 2019 - 03:25PM
Dow Jones News
By Colin Kellaher
Bristol-Myers Squibb Co. (BMY) on Tuesday said the European
Medicines Agency's Committee for Medicinal Products for Human Use
recommended approval of a flat-dosing schedule for its cancer drug
Opdivo in adults with the skin cancer melanoma.
The New York biopharmaceutical company said the committee's
positive opinion covers two-week and four-week flat dosing of
Opdivo for the adjuvant treatment of adults with melanoma with
involvement of lymph nodes or metastatic disease who have undergone
complete resection.
The European Commission, which generally follows the CHMP's
recommendations, will review the decision for final action,
Bristol-Myers said.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
September 24, 2019 09:10 ET (13:10 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
Von Feb 2024 bis Mär 2024
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
Von Mär 2023 bis Mär 2024